Targeted Liposomes Deliver Blood Pressure-Lowering Peptides Through the Gut More Effectively Than Free Peptides

The researchers used microfluidic self-assembly to create liposomes (from lecithin, cholesterol, and DSPE-β-glucan) encapsulating two ACE-inhibitory peptides derived from egg white proteins. Gastrointestinal stability was tested in vitro using simulated digestion. M cell targeting was assessed through Dectin-1 receptor interactions and Peyer's patch uptake studies. Antihypertensive efficacy was tested in spontaneously hypertensive rats using both single-dose and continuous administration protocols, measuring blood pressure along with markers of renin-angiotensin system activity, kidney function, cardiac function, and endothelial health.

Bioactive peptides from food are an attractive alternative to pharmaceutical blood pressure drugs, but their destruction during digestion has been a major barrier. This study demonstrates that smart delivery technology — using natural materials like β-glucan to target specific gut absorption pathways — can overcome this barrier and deliver meaningful blood pressure reduction. This bridges the gap between food science and drug delivery, potentially enabling functional foods that actually work.

The nutraceutical and functional food industries are growing rapidly, but a persistent criticism is that bioactive ingredients often can't survive digestion in meaningful amounts. Targeted nanodelivery systems like the one described here could validate the concept of food-as-medicine for specific conditions like hypertension. The use of β-glucan — itself a recognized health-promoting compound — as a targeting ligand is elegant because it adds its own health benefits while solving the delivery problem.

This is an animal study in spontaneously hypertensive rats, a model that may not perfectly represent human hypertension. The complexity of the delivery system (microfluidic assembly, specialized lipid components) may make large-scale manufacturing challenging and costly. Specific blood pressure values and degree of reduction are not reported in the abstract. Long-term safety of chronic liposome ingestion is not addressed. The peptides are derived from egg white, which may be problematic for people with egg allergies. Human bioavailability and efficacy remain to be demonstrated.